Anzeige
Meldung des Tages: Der nächste Bergbau-Boom, von dem noch niemand etwas weiß

Invesco Water Resources ETF Registered Shares News

ETF
WKN:  A2JNQQ ISIN:  US46137V1420 US-Symbol:  PHO
61,40 €
-3,55 €
-5,47%
25.06.26
Depot/Watchlist
Indexbildung
Ertragsverwendung
-
Lfd. Kosten
-
Fondsgröße
-  
Tracking Error
-
Währung
FWW Fundstars
keine Bewertung

Invesco Water Resources ETF Registered Shares News

03:38 Uhr - PR Newswire
Photocure ASA: Results for the third quarter of 2026
Photocure ASA: Results for the third quarter of 2026 PR Newswire
03:30 Uhr - PR Newswire
Photocure ASA: Results for the third quarter of 2026
Photocure ASA: Results for the third quarter of 2026 PR Newswire
22.10.26 - PR Newswire
Photocure ASA - New CFO Appointed
Photocure ASA - New CFO Appointed PR Newswire
22.10.26 - PR Newswire
Photocure ASA - New CFO Appointed
Photocure ASA - New CFO Appointed PR Newswire
14.08.26 - PR Newswire
Photocure Welcomes FDA Proposal to Initiate the Reclassification of Blue Light Cystoscopy Systems from Class III to Class II
Photocure Welcomes FDA Proposal to Initiate the Reclassification of Blue Light Cystoscopy Systems from Class III to Class II PR Newswire
14.08.26 - PR Newswire
Photocure Welcomes FDA Proposal to Initiate the Reclassification of Blue Light Cystoscopy Systems from Class III to Class II
Photocure Welcomes FDA Proposal to Initiate the Reclassification of Blue Light Cystoscopy Systems from Class III to Class II PR Newswire
11.08.26 - PR Newswire
Cost neutrality of BLC versus WLC in a real-world setting demonstrated by new OPTUM study in the U.S.
Cost neutrality of BLC versus WLC in a real-​world setting demonstrated by new OPTUM study in the U.S. PR Newswire
11.08.26 - PR Newswire
Cost neutrality of BLC versus WLC in a real-world setting demonstrated by new OPTUM study in the U.S.
Cost neutrality of BLC versus WLC in a real-​world setting demonstrated by new OPTUM study in the U.S. PR Newswire
29.07.26 - PR Newswire
Photocure ASA: Results for the second quarter of 2026
Photocure ASA: Results for the second quarter of 2026 PR Newswire
29.07.26 - PR Newswire
Photocure ASA: Results for the second quarter of 2026
Photocure ASA: Results for the second quarter of 2026 PR Newswire
08.06.26 - PR Newswire
Photocure and Artera to partner on digital pathology AI test evaluation for Bladder Cancer
Photocure and Artera to partner on digital pathology AI test evaluation for Bladder Cancer PR Newswire
08.06.26 - PR Newswire
Photocure and Artera to partner on digital pathology AI test evaluation for Bladder Cancer
Photocure and Artera to partner on digital pathology AI test evaluation for Bladder Cancer PR Newswire
04.06.26 - PR Newswire
Photocure ASA to Acquire Vesica Health Inc., Strengthening Leadership in Bladder Cancer Diagnostics
Photocure ASA to Acquire Vesica Health Inc., Strengthening Leadership in Bladder Cancer Diagnostics PR Newswire
04.06.26 - PR Newswire
Photocure ASA to Acquire Vesica Health Inc., Strengthening Leadership in Bladder Cancer Diagnostics
Photocure ASA to Acquire Vesica Health Inc., Strengthening Leadership in Bladder Cancer Diagnostics PR Newswire
18.05.26 - PR Newswire
AUA 2026: new studies demonstrated Blue Light Cystoscopy benefits in high-risk NMIBC management and cost comparison study
AUA 2026: new studies demonstrated Blue Light Cystoscopy benefits in high-risk NMIBC management and cost comparison study PR Newswire
18.05.26 - PR Newswire
AUA 2026: new studies demonstrated Blue Light Cystoscopy benefits in high-risk NMIBC management and cost comparison study
AUA 2026: new studies demonstrated Blue Light Cystoscopy benefits in high-risk NMIBC management and cost comparison study PR Newswire
07.05.26 - PR Newswire
Photocure ASA: Results for the first quarter of 2026
Photocure ASA: Results for the first quarter of 2026 PR Newswire
07.05.26 - PR Newswire
Photocure ASA: Results for the first quarter of 2026
Photocure ASA: Results for the first quarter of 2026 PR Newswire
04.05.26 - PR Newswire
New health economic methodology published: comparing cost-effectiveness of BLC versus NBI imaging technology in bladder cancer
New health economic methodology published: comparing cost-​effectiveness of BLC versus NBI imaging technology in bladder cancer PR Newswire
04.05.26 - PR Newswire
New health economic methodology published: comparing cost-effectiveness of BLC versus NBI imaging technology in bladder cancer
New health economic methodology published: comparing cost-​effectiveness of BLC versus NBI imaging technology in bladder cancer PR Newswire

Newssuche

Videos

newspaper
27.10.26 0,00%
Technical Trading: Ripple Zukauf Short
Ripple Short Typ: Turbo Open End WKN: BD7NA4 Hebel: 1,99 Laufzeit: OpenEnd Einstieg: Market ... Mehr »
Weitere Videos ❯

Weitere Vorteile:

  • Kursalarme
  • Watchlists & Musterdepots
  • Börsenspiele & Community-Forum
  • Historische Kurse im CSV-Format
  • News & Themen abonnieren